Comparing DAPSA, DAPSA28, and DAS28‐CRP in Patients With Psoriatic Arthritis Initiating a First Tumor Necrosis Factor Inhibitor Across Nine European Countries

Documenti analoghi

• Defining Bath Ankylosing Spondylitis Disease Activity Index Cut‐off Values for Disease Activity States in a Multinational European Cohort of Patients With Axial Spondyloarthritis
  di: Stylianos Georgiadis, et al.
  Pubblicazione: (2025)
• Sex Differences in the Effectiveness of First‐Line Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis: Results From the European Spondyloarthritis Research Collaboration Network
  di: Pasoon Hellamand, et al.
  Pubblicazione: (2024)
• ¿Es momento de adoptar el DAPSA para la evaluación de la Artritis Psoriásica?
  di: Enrique R. Soriano
  Pubblicazione: (2016)
• Machine Learning to Predict Remission Between 6 and 24 Months in Rheumatoid Arthritis: Insights From JAK, an International Registry Collaboration
  di: Zubeyir Salis, et al.
  Pubblicazione: (2026)
• Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease‐Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries
  di: Romain Aymon, et al.
  Pubblicazione: (2025)